Neovir solution 250mg/2ml ampoules 2ml, 5pcs

Composition

>1 ml of the solution contains: Active ingredient: Sodium oxodihydroacridinyl acetate (Neovir®) — 125 mgsupport substances: sodium citrate-2.5 mg; citric acid monohydrate-0.5-1.5 mg (up to pH 7.5–8.3); water for injection-up to 1 ml

Pharmacological action

An immunostimulating drug. It has antiviral activity against DNA and RNA genomic viruses. It has a pronounced anti-chlamydial effect. The activity of the drug is related to its ability to induce the formation of high titers of endogenous interferons in the body, especially interferon alpha.

Intravenous use of Neovir at a dose of 250 mg according to the detected serum interferon concentrations is equivalent to the use of 6-9 million mg. IU of recombinant interferon alpha.

Neovir activates bone marrow stem cells, T-lymphocytes, and macrophages. It exhibits immunomodulatory activity, normalizing the balance between subpopulations of T-helper and T-suppressor cells. In a number of diseases, Neovir is able to reduce the production of tumor necrosis factor in the body (HIV infection, herpes) and activate natural killer cells (in tumor diseases). Significantly increases the activity of polymorphonuclear leukocytes.

In HIV infection, Neovir has an immunomodulatory effect: it increases the absorption activity of blood serum, increases the ability of white blood cells to synthesize interferon alpha, and stimulates the formation of reactive oxygen species by phagocytes.

The peak of interferon activity in the blood and tissues is observed a few hours after Neovir use and persists for 16-20 hours.

Pharmacokinetics

Suction

When administered intravenously, the bioavailability of Neovir is more than 90%. After use of Neovir at a dose of 100-500 mg_{, cmax} in blood plasma is reached in 15-30 minutes and is 8.3 mcg / ml. After 5 hours, only minor concentrations of the Active ingredient are detected, and after 6 hours the drug is not detected in the blood plasma.

Serum interferon titers begin to increase 15-30 minutes after Neovir use. 2 peaks of interferon content in plasma were revealed: 70 IU / ml in 1.5-2 hours and 110 IU / ml in 8-10 hours, after which they begin to decrease. After 24 hours, the concentration of serum interferons remains quite high, and returns to the initial values after 46-48 hours.

Metabolism and elimination

It is not metabolized. T_1/2 is 1 h. It is excreted unchanged by the kidneys.

Indications

As an immunostimulating drug in a combination therapy: prevention and treatment of influenza and other acute respiratory diseases (including on the background of immunodeficiency States); infections caused by Herpes simplex virus type 1 and type 2 virus and Varicella zoster (including in patients with immune system disorders);

cytomegalovirus infection in patients with immunodeficiency;

radiation immunodeficiency; treatment of HIV infection;

encephalitis and encephalomyelitis viral etiology; acute and chronic hepatitis b and C;

urethritis, epididymitis, prostatitis, cervicitis and salpingitis chlamydial etiology;

lymphogranuloma venereum;

cancer;

multiple sclerosis;

candidiasis of skin and mucous membranes.

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Contraindications

Hypersensitivity, pregnancy, breast-feeding period.

Use with caution in elderly patients.

Side effects

General reactions:  low-grade fever, allergic reactions.

Local reactions:  local rapidly passing soreness at the injection site.

Interaction

During clinical studies and the use of the drug in clinical practice, there were no cases of incompatibility or potentiation of the drug’s action when interacting with other drugs.

There is no information on the physicochemical incompatibility of Neovir with other medicinal products.

How to take, course of use and dosage

The solution for injection is administered intravenously, a single dose is 250 mg (1 amp. ) or 4-6 mg/kg of body weight. If necessary, the single dose of Neovir can be increased to 500 mg.

The course of treatment, if there are no special instructions, consists of 5-7 intravenous injections in single doses with an interval of 48 hours. The course dose depends on the clinical picture. The course duration is 8-12 days. With long-term and preventive use, the interval between Neovir injections is 3-7 days.

For HIV infection, the solution for injection is used as part of a combination therapy. The course of treatment consists of 10 intravenous injections of 250 mg with an interval between injections of 48 hours. After the course of therapy, they take a break for 2 months. The number of repeated courses is not limited.

Overdose

Data on Neovir overdose were not provided.

Special instructions

In case of poor tolerance or pain at the site of intravenous use of the drug, it is recommended to administer Neovir together with 2 ml of 0.25-0.5% novocaine solution.

Form of production

Solution for intramuscular use

Storage conditions

Store in a dry place, protected from light, at a temperature of 15-25 °C

Shelf life

3 years

Active ingredient

Cridanimod

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as directed by your doctor

Indications

Urethritis, HIV infection, Cytomegalovirus infection, Herpes, Cancer, Inflammation of the female genital organs, Hepatitis, Chlamydia, Prostatitis, Flu